101
Antiplatelet Drug Resistances and Ischemic Events
Condition(s): Symptomatic Atherothrombosis Last Updated: September 9, 2009Active, not recruiting
153 Clinical Trials for: Platelet Reactivity, Page 6 of 8
Hide Studies Not Seeking New Volunteers
102
Pilot Study of Lychee Fruit Extract to Promote Cardiovascular Health
Condition(s): Cardiovascular Health Last Updated: August 19, 2010Completed
103
Thrombocyte Activity Reassessment and GEnoTyping for PCI(TARGET-PCI)
Condition(s): Coronary Artery Disease Last Updated: April 11, 2012Terminated
104
Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)
Condition(s): Diabetes Mellitus; Coronary Artery Disease Last Updated: February 19, 2010Completed
105
The Effect on Blood Cells, Known as Platelets, Using Prasugrel vs Clopidogrel in Patients With the Heart Problem Acute Coronary Syndrome (ACS)
Condition(s): Acute Coronary Syndrome Last Updated: August 25, 2010Completed
106
Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition
Condition(s): Percutaneous Coronary Intervention; Dual Antiplatelet Therapy; Aspirin; Clopidogrel Last Updated: April 19, 2012Recruiting
107
Pilot Study of Oligonol Supplementation to Promote Cardiovascular Health
Condition(s): Cardiovascular Health Last Updated: July 13, 2010Completed
108
A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)
Condition(s): Type 2 Diabetes Mellitus Last Updated: November 16, 2011Completed
109
Effects of the Consumption of California Walnuts on Cardiovascular Health
Condition(s): Cardiovascular Disease; Immune Health Last Updated: November 3, 2010Recruiting
110
A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)
Condition(s): Hypercholesterolemia Last Updated: November 23, 2011Completed
111
Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Body Mass Index ≥ 27
Condition(s): Cardiovascular Disease; Overweight Last Updated: January 12, 2012Recruiting
112
Dual Antiplatelet Therapy Tailored on the Extent of Platelet Inhibition
Condition(s): Unstable Angina; NSTEMI Last Updated: October 23, 2008Not yet recruiting
113
Clinical Assessment of Pidogrel® Versus Plavix® (CAPP)
Condition(s): Coronary Disease Last Updated: September 8, 2011Completed
114
Thromboelastography As A Tool for Possible Clopidogrel Resistance in The Patients Treated With Primary PCI for STEMI
Condition(s): Myocardial Infarction; Cardiovascular Disease Last Updated: August 16, 2007Not yet recruiting
115
Interaction Study of Clopidogrel 600/150 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects
Condition(s): Healthy Last Updated: December 14, 2011Completed
116
Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects
Condition(s): Healthy Last Updated: December 14, 2011Completed
117
Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Pantoprazole 80 mg in Healthy Subjects
Condition(s): Healthy Last Updated: December 14, 2011Completed
118
Interaction Study of Clopidogrel 300/75 mg Given Alone or With Omeprazole 80 mg 12 Hours Apart in Healthy Subjects
Condition(s): Healthy Last Updated: December 14, 2011Completed
119
Pharmacodynamic and Pharmacokinetic Study of 2 Different Dose Regimen of Clopidogrel in CYP2C19 Genotyped Healthy Subjects
Condition(s): Healthy Last Updated: December 14, 2011Completed
120
Platelet Function Assessment for Atherothrombotic Patients
Condition(s): Coronary Artery Disease Last Updated: January 20, 2011Recruiting
